Among the primary tumor gene mutations, 49 (46.7%) patients had a RAS mutation, 48 (45.7%) patients were RAS wild-type, 4 (3.8%) patients had a BRAF mutation and 93 (88.6%) patients were BRAF wild type. This evidence concerns the gene BRAF and neoplasm.